James Treco

CIK: 0001766070

Transaction Breakdown

Open Market Buys (P)1 (25.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (25.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

TNXP

Tonix Pharmaceuticals Holding Corp.

Director

Discretionary Trading P&L

Holdings

Transaction History (4 total)

TNXP
Tonix Pharmaceuticals Holding Corp.
May 12, 2026
Award(A)
Stock Option
Direct
22.7K shares-
TNXP
Tonix Pharmaceuticals Holding Corp.
Aug 20, 2025
Purchase(P)
Direct
250 shares at avg. $36.00$9K
TNXP
Tonix Pharmaceuticals Holding Corp.
May 13, 2025
Award(A)
Stock Option
Direct
10K shares-
TNXP
Tonix Pharmaceuticals Holding Corp.
Feb 5, 2025
Other(J)
Direct
0 shares at avg. $0.30$0.006

		Type	Shares	Price		Ownership
May 12, 2026	TNXP Tonix Pharmaceuticals Holding Corp.	Award(A) Stock Option	22,700	-	-	Direct
Aug 20, 2025	TNXP Tonix Pharmaceuticals Holding Corp.	Purchase(P)	250	$36.00	$9,000	Direct
May 13, 2025	TNXP Tonix Pharmaceuticals Holding Corp.	Award(A) Stock Option	10,000	-	-	Direct
Feb 5, 2025	TNXP Tonix Pharmaceuticals Holding Corp.	Other(J)	0	$0.30	$0	Direct

1-4 of 4 transactions

About Treco James

Treco James (SEC CIK 0001766070) files insider reports with the SEC as Director of Tonix Pharmaceuticals Holding Corp. (TNXP).

Signal8 holds 4 ownership filings by Treco James, all Form 4s, filed between Feb 28, 2025 and May 14, 2026. Those filings report 4 transactions, from Feb 5, 2025 to May 12, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Treco James's filings is in BERKELEY HEIGHTS, NJ.

Recent filings by Treco James

May 12, 2026: Grant or award of TNXP derivative securities (Form 4, code A).
Aug 20, 2025: Open-market purchase of TNXP shares (Form 4, code P).
May 13, 2025: Grant or award of TNXP derivative securities (Form 4, code A).
Feb 5, 2025: Other transaction of TNXP shares (Form 4, code J).

Other insiders filing for Tonix Pharmaceuticals Holding Corp. (TNXP)

Englese Thomas, Chief Commercial Officer
BAGGER RICHARD H, Director
SAENGER BRADLEY, Chief Financial Officer
Taylor Carolyn E., Director
Stillwell Richard Newcomb, Director
LEDERMAN SETH, Chief Executive Officer

How to read Form 4 transaction codes